Werewolf Therapeutics (HOWL) vs Heron Therapeutics (HRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Werewolf Therapeutics (HOWL) has outperformed Heron Therapeutics (HRTX) over the past year, gaining 8.4% versus a loss of 76.2%. Over five years, HOWL leads with a -93.7% price change compared with -97.3% for HRTX. Heron Therapeutics is the larger company by market cap ($48.0 million vs $46.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HOWL | HRTX |
|---|---|---|
| Share price | $0.9466 | $0.2525 |
| Market cap | $46.00M | $48.04M |
| 1-day change | -3.97% | -4.39% |
| YTD return | +49.31% | -80.58% |
| 1-year return | +8.43% | -76.18% |
| 5-year return | -93.68% | -97.32% |
| EPS (TTM) | $-0.58 | $-0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $154.90M |
| Revenue growth (YoY) | — | +7.36% |
| Net income (latest FY) | $-60.82M | $-20.20M |
| Gross margin | — | 73.31% |
| Operating margin | — | -1.64% |
| Net margin | — | -13.04% |
| 52-week high | $1.20 | $1.58 |
| 52-week low | $0.27 | $0.2479 |
| Distance from 52-week high | -21.12% | -84.02% |
| Analyst consensus | none | none |
| Avg. price target upside | +639.49% | +2672.28% |
| Average volume | 1.08M | 4.56M |
| Shares outstanding | 48.60M | 190.27M |
| Employees | 39 | 128 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HOWL has outperformed HRTX by 84.6 percentage points over the past year.
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
About Heron Therapeutics
HRTX stock →Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
HOWL vs HRTX FAQ
Which is bigger, Werewolf Therapeutics or Heron Therapeutics?
Heron Therapeutics (HRTX) is larger, with a market capitalization of $48.04M compared with $46.00M for Werewolf Therapeutics (HOWL).
Which stock has performed better over the past year, HOWL or HRTX?
HOWL returned +8.43% over the past 12 months, compared with -76.18% for HRTX (price return, excluding dividends). Past performance does not predict future results.
Are Werewolf Therapeutics and Heron Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.